Wounds (Dermatology) - Drugs in Development, 2021

November 2021 | 274 pages | ID: W8765F60B09DEN
Global Markets Direct

Abstracts

Wounds (Dermatology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Drugs In Development, 2021, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e., muscle, bone, nerves) following injury to the skin or underlying tissues/organs caused by surgery, a blow, a cut, chemicals, heat/cold, friction/shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 11, 8, 61, 11 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 15 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Wounds - Overview
Wounds - Therapeutics Development
Wounds - Therapeutics Assessment
Wounds - Companies Involved in Therapeutics Development
Wounds - Drug Profiles
Wounds - Dormant Projects
Wounds - Discontinued Products
Wounds - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Wounds, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Wounds - Pipeline by Adial Pharmaceuticals Inc, 2021
Wounds - Pipeline by AdiSave Inc, 2021
Wounds - Pipeline by Agile Sciences Inc, 2021
Wounds - Pipeline by AiViva BioPharma Inc, 2021
Wounds - Pipeline by AlgiPharma AS, 2021
Wounds - Pipeline by Allander Biotechnologies LLC, 2021
Wounds - Pipeline by Alliance Pharma Plc, 2021
Wounds - Pipeline by AMNICELL Corp Ltd, 2021
Wounds - Pipeline by Amniotics AB, 2021
Wounds - Pipeline by Ankasa Regenerative Therapeutics Inc, 2021
Wounds - Pipeline by Apidel SA, 2021
Wounds - Pipeline by Aposcience AG, 2021
Wounds - Pipeline by Araim Pharmaceuticals Inc, 2021
Wounds - Pipeline by Arava Bio-Tech Ltd, 2021
Wounds - Pipeline by Arrevus Inc, 2021
Wounds - Pipeline by Auxagen Inc, 2021
Wounds - Pipeline by Avalon GloboCare Corp, 2021
Wounds - Pipeline by Axolo Pharma Inc, 2021
Wounds - Pipeline by Bacainn Therapeutics Inc, 2021
Wounds - Pipeline by Biomendics LLC, 2021
Wounds - Pipeline by BioNTech SE, 2021
Wounds - Pipeline by Bopin (Shanghai) Biomedical Technology Co Ltd, 2021
Wounds - Pipeline by Cannabis Science Inc, 2021
Wounds - Pipeline by Canton Biotechnologies Inc, 2021
Wounds - Pipeline by Causeway Therapeutics Ltd, 2021
Wounds - Pipeline by Cellphire Inc, 2021
Wounds - Pipeline by CK Regeon Inc, 2021
Wounds - Pipeline by Clene Inc, 2021
Wounds - Pipeline by Connext Co Ltd, 2021
Wounds - Pipeline by Crioestaminal Saude e Tecnologia SA, 2021
Wounds - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Wounds - Pipeline by Destiny Pharma Plc, 2021
Wounds - Pipeline by Exogenus Therapeutics SA, 2021
Wounds - Pipeline by Exopharm Ltd, 2021
Wounds - Pipeline by EyeGene Inc, 2021
Wounds - Pipeline by Resolys Bio Inc, 2021
Wounds - Pipeline by Reven Holdings Inc, 2021
Wounds - Pipeline by Revive Therapeutics Ltd, 2021
Wounds - Pipeline by RION Health Inc, 2021
Wounds - Pipeline by Riptide Bioscience Inc, 2021
Wounds - Pipeline by Scarless Laboratories Inc, 2021
Wounds - Pipeline by SERDA Therapeutics BV, 2021
Wounds - Pipeline by SomaGenics Inc, 2021
Wounds - Pipeline by Tego Science Inc, 2021
Wounds - Pipeline by TGV-Inhalonix Inc, 2021
Wounds - Pipeline by Thesan Pharmaceuticals Inc, 2021
Wounds - Pipeline by Topadur Pharma AG, 2021
Wounds - Pipeline by Transwell Biotech Co Ltd, 2021
Wounds - Pipeline by Traverse Biosciences Inc, 2021
Wounds - Pipeline by Tumorend LLC, 2021
Wounds - Pipeline by Valitor Inc, 2021
Wounds - Pipeline by Vascular BioSciences, 2021
Wounds - Pipeline by VascVersa Ltd, 2021
Wounds - Pipeline by Vasomune Inc, 2021
Wounds - Pipeline by viDA Therapeutics Inc, 2021
Wounds - Pipeline by Viridian Therapeutics Inc, 2021
Wounds - Pipeline by Yabao Pharmaceutical Group Co Ltd, 2021
Wounds - Pipeline by Zih Yuan Tang Biotechnology Co Ltd, 2021
Wounds - Pipeline by ZZ Biotech LLC, 2021
Wounds - Dormant Projects, 2021
Wounds - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Wounds, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021